Genomic Health, Inc. is a healthcare firm that provides genomic diagnostic tests to personalize cancer treatment. The company has market cap of $1.08 billion. The Firm develops and commercializes genomic clinical laboratory services. It currently has negative earnings. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Coastline Trust Co increased Telekomunikasi Indonesia Adr (TLK) stake by 98.65% reported in 2016Q4 SEC filing. Coastline Trust Co acquired 31,865 shares as Telekomunikasi Indonesia Adr (TLK)’s stock declined 12.94%. The Coastline Trust Co holds 64,165 shares with $1.87M value, up from 32,300 last quarter. Telekomunikasi Indonesia Adr now has $30.42 billion valuation. The stock declined 1.01% or $0.31 reaching $30.32 on the news. About 71,441 shares traded. Telekomunikasi Indones (Prsr)Tbk PT-ADR (NYSE:TLK) has declined 0.36% since September 12, 2016 and is downtrending. It has underperformed by 8.84% the S&P500.
About 135,777 shares traded or 16.30% up from the average. Genomic Health, Inc. (NASDAQ:GHDX) has risen 12.56% since September 12, 2016 and is uptrending. It has outperformed by 4.08% the S&P500.
Ratings analysis reveals 38% of Genomic Health’s analysts are positive. Out of 8 Wall Street analysts rating Genomic Health, 3 give it “Buy”, 1 “Sell” rating, while 4 recommend “Hold”. The lowest target is $25 while the high is $44. The stock’s average target of $32.20 is 0.72% above today’s ($31.97) share price. GHDX was included in 19 notes of analysts from August 5, 2015. Zacks downgraded the stock to “Hold” rating in Thursday, August 6 report. The rating was downgraded by Cowen & Co to “Market Perform” on Wednesday, January 4. The company was upgraded on Wednesday, November 4 by Raymond James. Zacks upgraded the stock to “Sell” rating in Monday, August 24 report. On Wednesday, August 17 the stock rating was maintained by Jefferies with “Hold”. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Outperform” rating by Cowen & Co on Thursday, November 19. The stock of Genomic Health, Inc. (NASDAQ:GHDX) earned “Buy” rating by UBS on Monday, November 23. As per Monday, January 11, the company rating was downgraded by Piper Jaffray. Canaccord Genuity upgraded Genomic Health, Inc. (NASDAQ:GHDX) rating on Wednesday, January 6. Canaccord Genuity has “Buy” rating and $44 target. Raymond James upgraded the shares of GHDX in report on Friday, August 28 to “Market Perform” rating.
Analysts await Genomic Health, Inc. (NASDAQ:GHDX) to report earnings on May, 3. They expect $-0.04 earnings per share, up 82.61% or $0.19 from last year’s $-0.23 per share. After $0.04 actual earnings per share reported by Genomic Health, Inc. for the previous quarter, Wall Street now forecasts -200.00% negative EPS growth.
Baker Bros. Advisors Lp holds 3.97% of its portfolio in Genomic Health, Inc. for 13.77 million shares. Camber Capital Management Llc owns 2.46 million shares or 3.76% of their US portfolio. Moreover, Emory University has 1.86% invested in the company for 64,147 shares. The Virginia-based Motley Fool Asset Management Llc has invested 0.86% in the stock. Tributary Capital Management Llc, a Colorado-based fund reported 237,371 shares.
